ENMD-2076 not checked

CASI pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma, Advanced Cancer, Multiple Myeloma
Main trialPhase 2
“The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time.”In the company’s words, NCT02234986 on ClinicalTrials.gov

Other drugs for Advanced Cancer

All 2440 drugs for Advanced Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Completed 30 Jun 2018 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Phase 1Completed Dec 2010 A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
Phase 1Completed Nov 2011 Study of ENMD-2076 in Patients With Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ENMD-2076

Following is part of Solo: you see every change to ENMD-2076 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in